Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81236 | 0.89 | CYP2A6 (0.58) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL2792315 | 0.83 | CYP2A6 (0.67) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL30003342 | 0.83 | CYP2A6 (0.67) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL5546289 | 0.80 | CYP2A6 (0.62) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL31547776 | 0.80 | CYP2A6 (0.71) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL908324 | 0.80 | CYP2A6 (0.74) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL1304400 | 0.80 | CYP2A6 (0.62) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL5472938 | 0.80 | CYP2A6 (0.62) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL277679 | 0.80 | CYP2A6 (0.71) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP | |
| SCHEMBL7427114 | 0.80 | CYP2A6 (0.62) | CYP2A6SMN1; SMN2IDO1CHRNA7CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195478-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4487913-A2 | OPIOID RECEPTOR MODULATORS | The Trustees Of Columbia University In The City Of New York (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3224261-B1 | OPIOID RECEPTOR MODULATORS | UNIV COLUMBIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| EP-0831824-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0822814-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0831824-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0822814-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-02-11 | — | — | EP | disclosed |
| US-5668148-A | BENIGN PROSTATIC HYPERTROPHY | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1996039140-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996032938-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0292840-B1 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5175157-A | Cardiovascular disorders | BOEHRINGER INGELHEIM GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0292840-A2 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195478-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | CYP2A6 627/4885SMN1; SMN2 3917/4885IDO1 433/4885 |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | CYP2A6 627/4885SMN1; SMN2 3917/4885IDO1 433/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | CYP2A6 627/4885SMN1; SMN2 3917/4885IDO1 433/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | CYP2A6 514/4885SMN1; SMN2 4640/4885IDO1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.